Biohaven Ltd. Debt Instrument, Fair Value Disclosure
Biohaven Ltd. (BHVN) had Debt Instrument, Fair Value Disclosure of $259.48 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:DebtInstrumentFairValue · last filed 2026-08-10
- 2026-06-30: Debt Instrument, Fair Value Disclosure $259.48M.
- 2026-03-31: Debt Instrument, Fair Value Disclosure $241.91M.
- 2025-12-31: Debt Instrument, Fair Value Disclosure $238.90M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $259.48M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $241.91M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $238.90M 10-Q · filed 2026-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |